New Century Health Associate Chief Medical Officer Dr. Monica Soni explores some of the most prevalent health inequities in cancer care and shares strategies for how to address them.
Which components of the recently announced Cancer Moonshot should get high priority for the initiative to s...
How do social determinants of health impact outcomes in cancer care? New Century Health Associate CMO Dr. Monica Soni and Radiation Oncologist Dr. Onyinye Balogun discuss.
New Century Health and our Vital Decisions solution seek to ensure more cancer patients receive end-of-life care that aligns with their wishes.
NCH’s high-value clinical oncology pathways, patient triage programs and provider engagement strategies help community practice to succeed in value-based payment program.
The predicted wave of late-stage cancers is taking longer to materialize than we expected.
Which components of the recently announced Cancer Moonshot should get high priority for the initiative to succeed? Our chief medical officer, Dr. Andrew Hertler, outlines three key questions to track.
Dr. Andrew Hertler explains three key criteria for evaluating fast-tracked drugs.
Confronting the heart-wrenching, avoidable circumstances that happen in hospitals and homes every day.
Red flags cause clinical reviewers to question a radiation oncologist’s diagnosis.
Health plan clinical leaders joined us for an insightful discussion on the path toward high-value cancer care.
Home-based chemotherapy infusions may offer convenience but also raise a host of questions.
Discussing drug costs should be a core tenet of shared decision-making.
Sotunde is president and CEO of Blue Cross and Blue Shield of North Carolina.
Partnership will empower members with serious illness to articulate and advocate for the care they want.
Evidence-Based Oncology interviews our CMO about mismatches between drug costs and efficacy.
Our CMO speaks with Managed Care Executive about the promise and perils of genomic testing.
Modern Healthcare spoke with NCH's Dr. Andrew Hertler about problems in the FDA's approval process.
Our CMO speaks with Formulary Watch about the challenges of high--cost drugs with marginal benefit.
The addition of Vital Decisions’ specialized patient engagement services expected to position New Century Health to accelerate growth, improve patient care quality and increase margins.
The FDA's Aduhelm approval was highly controversial, but not as surprising for those who follow the oncology drug pipeline.
Our chief medical officer highlights noteworthy research and results from clinical oncology's premier event.